Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 84 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016', provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics. 

The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha-Synuclein (alphaSyn or SNCA)
- The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha-Synuclein (alphaSyn or SNCA) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Alpha-Synuclein (alphaSyn or SNCA) Overview 9
Therapeutics Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Stage of Development 10
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Therapy Area 11
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Indication 12
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Companies 15
Alpha-Synuclein (alphaSyn or SNCA) - Products under Development by Universities/Institutes 18
Alpha-Synuclein (alphaSyn or SNCA) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Alpha-Synuclein (alphaSyn or SNCA) - Companies Involved in Therapeutics Development 26
AC Immune SA 26
AFFiRiS AG 27
BioArctic Neuroscience AB 28
Biogen, Inc. 29
NeuroPhage Pharmaceuticals, Inc. 30
Neuropore Therapies, Inc. 31
nLife Therapeutics, S.L. 32
Primary Peptides, Inc. 33
Prothena Corporation Plc 34
QR Pharma, Inc. 35
reMYND NV 36
Synovo GmbH 37
Alpha-Synuclein (alphaSyn or SNCA) - Drug Profiles 38
BAN-0805 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
BIIB-054 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
CLR-01 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
DPC-003 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Kenterin - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
NLFPD-1233 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
NPT-001 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
NPT-002 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
NPT-005 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
NPT-088 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
NPT-133 - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NPT-20011 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NPT-3G - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
PD-01 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
PD-03 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
PD-04 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Posiphen - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
PP-003 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
PRX-002 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
quinpramine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ReS-12S - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
ReS-9S - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
trehalose - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Vaccine to Target Alpha-Synuclein for Parkinson's Disease - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Alpha-Synuclein (alphaSyn or SNCA) - Dormant Projects 72
Alpha-Synuclein (alphaSyn or SNCA) - Featured News & Press Releases 74
Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11 74
Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials 74
Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference 74
Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer's Association International Conference 75
Jul 02, 2015: BIIB054 reached significant milestone 75
Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease 75
Jun 15, 2015: BioArctic Neuroscience Parkinson's disease program receives grant from VINNOVA 76
Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders 77
Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson's disease 77
Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease 78
Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer's & Parkinson's Diseases 79
Dec 09, 2014: Parkinson's Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS 79
Nov 14, 2014: NeuroPhage's GAIM Technology Chosen As Top Project To Watch For The Therapeutic Area Partnerships Conference 80
Aug 26, 2014: Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress 80
Jul 31, 2014: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 81
Appendix 83
Methodology 83
Coverage 83
Secondary Research 83
Primary Research 83
Expert Panel Validation 83
Contact Us 83
Disclaimer 84

List of Tables

Number of Products under Development for, H1 2016 10
Number of Products under Development by Therapy Area, H1 2016 11
Number of Products under Development by Indication, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Assessment by Monotherapy/Combination Products, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Pipeline by AC Immune SA, H1 2016 26
Pipeline by AFFiRiS AG, H1 2016 27
Pipeline by BioArctic Neuroscience AB, H1 2016 28
Pipeline by Biogen, Inc., H1 2016 29
Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016 30
Pipeline by Neuropore Therapies, Inc., H1 2016 31
Pipeline by nLife Therapeutics, S.L., H1 2016 32
Pipeline by Primary Peptides, Inc., H1 2016 33
Pipeline by Prothena Corporation Plc, H1 2016 34
Pipeline by QR Pharma, Inc., H1 2016 35
Pipeline by reMYND NV, H1 2016 36
Pipeline by Synovo GmbH, H1 2016 37
Dormant Projects, H1 2016 72
Dormant Projects (Contd..1), H1 2016 73